Xanthic Biopharma Inks Strategic Partnership With Avitas CBD Water

CANADA: Xanthic Biopharma (formerly Aurquest Resources Inc.) has announced a licensing and strategic partnership agreement with Avitas CBD Water.

Avitas, based in Portland, Oregon, will be producing and distributing CBD-infused water, co-branded with “Powered by Xanthic Solubles.”  Under the terms of the Agreement, Xanthic is making a strategic investment in Avitas, acquiring a 45% ownership position in exchange for a cash payment of USD$600,000 and the issuance of up to 600,000 common shares of Xanthic, with an aggregate value of USD$300,000 at USD$0.50 per common share, subject to certain performance milestones over the next 12 months.

Avitas is currently seeking distribution, and is planning to be in production by April 2018.

Ryan Maxson, Co-Founder and CEO of Avitas comments, “We are proud to be one of the first companies to license the Xanthic brand and look forward to entering the West Coast market.  Our team has over two decades of combined experience in both the food and cannabinoid industries.  With our vision and Xanthic’s support, we expect to make waves in the infused water category.”

Tim Moore, the CEO of Xanthic, states, “This strategic partnership is Xanthic’s first step in proving that our proprietary technology is a viable licensing investment for producers and distributors across North America. We’re thrilled to be able to not only license our brand to Avitas, but to also work as a strategic partner to assist Avitas with their penetration of the infused water market. Moving forward, our corporate vision is to continue to provide the “Powered by Xanthic” technology to producers and distributors across various product categories and in multiple jurisdictions.”

 

Israel’s Tikun Olam Continues U.S. Expansion

Deal with DC Cultivator Alternative Solutions Brings Renowned Cannabis Products to the Nation’s Capital 

NEW YORK:  Tikun Olam, a leading Israeli cannabis brand and pioneer in cannabis research, continues its U.S. expansion by partnering with Washington DC cultivator Alternative Solutions. The just-inked licensing deal allows Alternative Solutions to grow, manufacture and distribute Tikunbranded products to all five District of Columbia dispensaries.

Tikun Olam’s award-winning premium cannabis products are backed by years of peer-reviewed scientific research and unprecedented clinical data collection, which has shown to deliver symptomatic relief to those suffering from specific conditions such as cancer, PTSD, epilepsy, Crohn’s Disease/Colitis, chronic pain and neuropathy, to name a few. At the  held November 30 in Toronto, Tikun strains took First place in three categories: Top High THC Flower (Eran Almog), Top High CBD Flower  (Avidekel), and Top High CDB Oil (Avidekel), in addition to placing Second in Top Hybrid Flower (Midnight). Tikun’s full line of proprietary strain products–from flower, vape, topicals and tinctures–will be available in Washington DC  beginning in 2018.

“Alternative Solutions is thrilled to be Tikun Olam’s exclusive partner in DC,” says Matt Lawson-Baker, COO of Alternative Solutions. “We look forward to making Tikun’s products available at all DC dispensaries, giving access to these clinically proven strains to the more than 5,600 registered MMJ patients in Washington DC.”

The new five-year deal with Alternative Solutions is the latest in a series of licensing agreements struck since Tikun’s U.S. launch in 2015 in Delaware. The recent announcement with the MariMed cannabis network will introduce Tikun’s exclusive strains and products in medical marijuana dispensaries in Rhode Island, Maryland, Massachusetts and Illinois in 2018. Tikun™ products also launched in Nevada in March 2017 and in Washington State in November.